The adenosinergic system :
The adenosinergic system : a non-dopaminergic target in parkinson’s disease /
edited by Micaela Morelli, Nicola Simola, Jadwiga Wardas.
- 1st ed. 2015.
- xii, 337 páginas : 41 ilustraciones, 31 ilustraciones en color.
- Current Topics in Neurotoxicity, 10 2363-9563 ; .
Springer eBooks
Adenosine A2A receptors: localization and function -- Allosteric Mechanisms in the adenosine A2A-dopamine D2 receptor heteromer -- Adenosine A2A receptor antagonists in drug development -- Adenosine A2A Receptors and Neurotrophic Factors: Relevance for Parkinson's Disease -- Role of adenosine A2A receptors in the control of neuroinflammation – relevance for Parkinson’s disease -- Purines in Parkinson's: Adenosine A2A receptors and urate as targets for neuroprotection -- Adenosine A2A receptor antagonists as drugs for symptomatic control of Parkinson’s disease in preclinical studies -- Dopamine/adenosine interactions related to tremor in animal models of Parkinsonism -- Adenosine A2A receptor antagonists in L-DOPA-induced motor fluctuations -- Adenosine A2A receptor-mediated control of non-motor functions in Parkinson’s disease -- Imaging Studies with A2A Receptor Antagonists -- Caffeine and neuroprotection in Parkinson's disease -- The story of istradefylline – the first approved A2A antagonist for the treatment of Parkinson’s disease -- Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson's Disease -- Adenosinergic regulation of sleep-wake behavior in the basal ganglia.
9783319202730
RC321-580
Springer eBooks
Adenosine A2A receptors: localization and function -- Allosteric Mechanisms in the adenosine A2A-dopamine D2 receptor heteromer -- Adenosine A2A receptor antagonists in drug development -- Adenosine A2A Receptors and Neurotrophic Factors: Relevance for Parkinson's Disease -- Role of adenosine A2A receptors in the control of neuroinflammation – relevance for Parkinson’s disease -- Purines in Parkinson's: Adenosine A2A receptors and urate as targets for neuroprotection -- Adenosine A2A receptor antagonists as drugs for symptomatic control of Parkinson’s disease in preclinical studies -- Dopamine/adenosine interactions related to tremor in animal models of Parkinsonism -- Adenosine A2A receptor antagonists in L-DOPA-induced motor fluctuations -- Adenosine A2A receptor-mediated control of non-motor functions in Parkinson’s disease -- Imaging Studies with A2A Receptor Antagonists -- Caffeine and neuroprotection in Parkinson's disease -- The story of istradefylline – the first approved A2A antagonist for the treatment of Parkinson’s disease -- Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson's Disease -- Adenosinergic regulation of sleep-wake behavior in the basal ganglia.
9783319202730
RC321-580